Placebo + Linagliptin

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 2

Conditions

Diabetes Mellitus, Type 2

Trial Timeline

Oct 1, 2009 โ†’ โ€”

About Placebo + Linagliptin

Placebo + Linagliptin is a phase 3 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT00996658. Target conditions include Diabetes Mellitus, Type 2.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (5)

NCT IDPhaseStatus
NCT02240680ApprovedCompleted
NCT01897532ApprovedCompleted
NCT01214239Phase 3Completed
NCT00996658Phase 3Completed
NCT00954447Phase 3Completed